FindTrial
Sign In

METRONOMIC THERAPY ,ORAL SOMMINISTRATION OF LOW DOSES OF CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CARCINOMA

METRONOMIC THERAPY ,ORAL SOMMINISTRATION OF LOW DOSES OF CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CARCINOMA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004448-30-IT
Enrollment
Unknown
Registered
2007-11-09
Start date
2005-01-17
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HORMONE-REFRACTORY PROSTATE CARCINOMA MedDRA version: 6.1 Level: PT Classification code 10029096

Interventions

Trade Name: ENDOXAN BAXTER*50CPR RIV 50MG Pharmaceutical Form: Tablet INN or Proposed INN: Cyclophosphamide CAS Number: 6055-19-2 Concentration unit: mg milligram(s) Concentration type: equal Concentr

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026